Clinical trial
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or…
NCT00004199 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00004199 |
|---|---|
| Title | Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor Prinomastat (AG3340) in Combination With Gemcitabine and Cisplatin in Patients Having Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | cisplatin, gemcitabine hydrochloride, prinomastat |
| Start date | Mar 1, 1999 |
| Primary completion | Jul 1, 2001 |
| First posted | Jul 19, 2004 |
| Last update posted | Aug 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: